FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361946022> ?p ?o ?g. }

• W4361946022 abstract "<div>Abstract<p><b>Purpose:</b> Somatic mutations in <i>IDH1/2</i> occur in approximately 20% of patients with myeloid neoplasms, including acute myeloid leukemia (AML). IDH1/2^MUT enzymes produce <i>D</i>-2-hydroxyglutarate (<i>D</i>2HG), which associates with increased DNA damage and improved responses to chemo/radiotherapy and PARP inhibitors in solid tumor cells. Whether this also holds true for <i>IDH1/2</i>^MUT AML is not known.</p><p><b>Experimental Design:</b> Well-characterized primary <i>IDH1</i>^MUT, <i>IDH2</i>^MUT, and <i>IDH1/2</i>^WT AML cells were analyzed for DNA damage and responses to daunorubicin, ionizing radiation, and PARP inhibitors.</p><p><b>Results:</b> <i>IDH1/2</i>^MUT caused increased DNA damage and sensitization to daunorubicin, irradiation, and the PARP inhibitors olaparib and talazoparib in AML cells. IDH1/2^MUT inhibitors protected against these treatments. Combined treatment with a PARP inhibitor and daunorubicin had an additive effect on the killing of <i>IDH1/2</i>^MUT AML cells. We provide evidence that the therapy sensitivity of <i>IDH1/2</i>^MUT cells was caused by <i>D</i>2HG-mediated downregulation of expression of the DNA damage response gene <i>ATM</i> and not by altered redox responses due to metabolic alterations in <i>IDH1/2</i>^MUT cells.</p><p><b>Conclusions:</b> <i>IDH1/2</i>^MUT AML cells are sensitive to PARP inhibitors as monotherapy but especially when combined with a DNA-damaging agent, such as daunorubicin, whereas concomitant administration of IDH1/2^MUT inhibitors during cytotoxic therapy decrease the efficacy of both agents in <i>IDH1/2</i>^MUT AML. These results advocate in favor of clinical trials of PARP inhibitors either or not in combination with daunorubicin in <i>IDH1/2</i>^MUT AML. <i>Clin Cancer Res; 24(7); 1705–15. ©2018 AACR</i>.</p></div>" @default.
• W4361946022 created "2023-04-05" @default.
• W4361946022 creator A5015705148 @default.
• W4361946022 creator A5016810759 @default.
• W4361946022 creator A5019215418 @default.
• W4361946022 creator A5033165278 @default.
• W4361946022 creator A5033704013 @default.
• W4361946022 creator A5039388919 @default.
• W4361946022 creator A5050620740 @default.
• W4361946022 creator A5055740968 @default.
• W4361946022 creator A5063314967 @default.
• W4361946022 creator A5070456575 @default.
• W4361946022 creator A5085918635 @default.
• W4361946022 creator A5085974329 @default.
• W4361946022 creator A5089069968 @default.
• W4361946022 creator A5090717354 @default.
• W4361946022 date "2023-03-31" @default.
• W4361946022 modified "2023-09-26" @default.
• W4361946022 title "Data from <i>IDH1/2</i> Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors" @default.
• W4361946022 doi "https://doi.org/10.1158/1078-0432.c.6525927" @default.
• W4361946022 hasPublicationYear "2023" @default.
• W4361946022 type Work @default.
• W4361946022 citedByCount "0" @default.
• W4361946022 crossrefType "posted-content" @default.
• W4361946022 hasAuthorship W4361946022A5015705148 @default.
• W4361946022 hasAuthorship W4361946022A5016810759 @default.
• W4361946022 hasAuthorship W4361946022A5019215418 @default.
• W4361946022 hasAuthorship W4361946022A5033165278 @default.
• W4361946022 hasAuthorship W4361946022A5033704013 @default.
• W4361946022 hasAuthorship W4361946022A5039388919 @default.
• W4361946022 hasAuthorship W4361946022A5050620740 @default.
• W4361946022 hasAuthorship W4361946022A5055740968 @default.
• W4361946022 hasAuthorship W4361946022A5063314967 @default.
• W4361946022 hasAuthorship W4361946022A5070456575 @default.
• W4361946022 hasAuthorship W4361946022A5085918635 @default.
• W4361946022 hasAuthorship W4361946022A5085974329 @default.
• W4361946022 hasAuthorship W4361946022A5089069968 @default.
• W4361946022 hasAuthorship W4361946022A5090717354 @default.
• W4361946022 hasBestOaLocation W43619460222 @default.
• W4361946022 hasConcept C104317684 @default.
• W4361946022 hasConcept C127848430 @default.
• W4361946022 hasConcept C153911025 @default.
• W4361946022 hasConcept C185592680 @default.
• W4361946022 hasConcept C2776059313 @default.
• W4361946022 hasConcept C501734568 @default.
• W4361946022 hasConcept C502942594 @default.
• W4361946022 hasConcept C55493867 @default.
• W4361946022 hasConcept C86803240 @default.
• W4361946022 hasConceptScore W4361946022C104317684 @default.
• W4361946022 hasConceptScore W4361946022C127848430 @default.
• W4361946022 hasConceptScore W4361946022C153911025 @default.
• W4361946022 hasConceptScore W4361946022C185592680 @default.
• W4361946022 hasConceptScore W4361946022C2776059313 @default.
• W4361946022 hasConceptScore W4361946022C501734568 @default.
• W4361946022 hasConceptScore W4361946022C502942594 @default.
• W4361946022 hasConceptScore W4361946022C55493867 @default.
• W4361946022 hasConceptScore W4361946022C86803240 @default.
• W4361946022 hasLocation W43619460221 @default.
• W4361946022 hasLocation W43619460222 @default.
• W4361946022 hasOpenAccess W4361946022 @default.
• W4361946022 hasPrimaryLocation W43619460221 @default.
• W4361946022 hasRelatedWork W2038557641 @default.
• W4361946022 hasRelatedWork W2074200851 @default.
• W4361946022 hasRelatedWork W2117996853 @default.
• W4361946022 hasRelatedWork W2128680685 @default.
• W4361946022 hasRelatedWork W2185182801 @default.
• W4361946022 hasRelatedWork W2588385654 @default.
• W4361946022 hasRelatedWork W2595719683 @default.
• W4361946022 hasRelatedWork W2751837787 @default.
• W4361946022 hasRelatedWork W2991465574 @default.
• W4361946022 hasRelatedWork W3110028750 @default.
• W4361946022 isParatext "false" @default.
• W4361946022 isRetracted "false" @default.
• W4361946022 workType "article" @default.